SCHEMBL6696959

SCHEMBL6696959

O=C(Cc1cscc1NS(=O)(=O)c1ccc(C(F)(F)F)cc1C(F)(F)F)N1CCOCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.43
ALDH1A1 P00352 5/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MCOLN3 Q8TDD5 1/20 0.43
KMT2A Q03164 1/20 0.42
FKBP1A P62942 1/20 0.40
POLB P06746 1/20 0.40
LRRK2 Q5S007 1/20 0.39
HPGD P15428 1/20 0.38
CASP1 P29466 1/20 0.38
HTT P42858 1/20 0.38
CASP7 P55210 1/20 0.38
HSD17B10 Q99714 1/20 0.38
HSD11B1 P28845 1/20 0.38
CNR2 P34972 1/20 0.38
F2 P00734 1/20 0.38
NAMPT P43490 1/20 0.38
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37
CCKBR P32239 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6697456 0.91 GRIN1 (0.46) LMNAALDH1A1SMN1; SMN2MCOLN3KMT2A
SCHEMBL6699924 0.84 ALDH1A1 (0.43) LMNAALDH1A1SMN1; SMN2MCOLN3KMT2A
SCHEMBL3608224 0.82 HSD11B1 (0.60) LMNAALDH1A1SMN1; SMN2MCOLN3KMT2A
SCHEMBL7080427 0.81 KMT2A (0.47) LMNAALDH1A1SMN1; SMN2KMT2APOLB
SCHEMBL3255071 0.81 HSD11B1 (0.49) LMNAALDH1A1SMN1; SMN2MCOLN3KMT2A
SCHEMBL5831393 0.81 GAA (0.46) LMNAALDH1A1SMN1; SMN2MCOLN3KMT2A
SCHEMBL6679923 0.80 MAPT (0.43) LMNAALDH1A1KMT2ALRRK2HPGD
SCHEMBL5831585 0.80 SCN9A (0.43) LMNAALDH1A1SMN1; SMN2MCOLN3KMT2A
SCHEMBL6699043 0.79 HSD11B1 (0.51) LMNASMN1; SMN2KMT2APOLBHPGD
SCHEMBL6695594 0.79 PKM (0.42) LMNAALDH1A1SMN1; SMN2MCOLN3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO claimed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO disclosed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 LMNA 1976/4885ALDH1A1 47/4885SMN1; SMN2 3179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.